Targeting Cellular Immunity to Generate a Robust Antitumor Response
Biocytics’ diverse portfolio of cell therapy research and development leverages the intrinsic specificity of autologous immune cells for the potential to treat solid tumors. The current research pipeline is comprised of lymphoid lineage cells including αβ T cells enriched for TAA-specific clones, memory NK cells, and γδ T cells. By developing products from different cell types we seek to maximize potential patient benefit based on tumor type, biomarkers, and immune infiltration in the TME.
Our discovery and pre-clinical development process is informed by three core principles: (1) Point-of-care collection, expansion, and formulation, (2) Inherent receptor specificity of autologous lymphocytes, and a (3) Proprietary ex-vivo culture system. Generating effector cells from different immune cell lineages allows them to identify and target cancer cells in a pleiotropic manner. Rather than using a chimeric antigen receptor (CAR) with a single or dual specificity, BioCytics’ cellular fractions can broadly target cancer by recognition of mutated tumor peptides, phosphoantigens, HLA downregulation, and/or innate signals of cellular stress.
It is hypothesized that by administering individually or in combination TAA-specific aβ T cells, NK cells, and γδ T cells, in-vitro-expanded autologous immune cells may synergize to yield robust antitumor activity*.